Evidence map›Paper›PMID 25848976›Full record

ArticleThe Journal of investigative dermatology2015

Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.

Shenying Fang, Yuling Wang, Yun S Chun, Huey Liu, Merrick I Ross, Jeffrey E Gershenwald, Janice N Cormier, Richard E Royal, Anthony Lucci, Christopher W Schacherer and 8 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Shenying FangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; These authors contributed equally to this work. Electronic address: sfang@mdanderson.org.
Yuling WangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yun S ChunDepartment of Surgery, Virginia Piper Cancer Institute, Minneapolis, Minnesota, USA.
Huey LiuDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Merrick I RossDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey E GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: jelee@mdanderson.org.
Janice N CormierDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Richard E RoyalDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anthony LucciDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christopher W SchachererDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
John D ReveilleDivision of Rheumatology and Clinical Immunogenetics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Wei ChenDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dawen SuiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roland L BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Li-E WangDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Qingyi WeiDuke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Christopher I AmosGeisel College of Medicine, Community and Family Medicine, Dartmouth College, Lebanon, New Hampshire, USA; These authors contributed equally to this work.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; These authors contributed equally to this work.
The University of Texas MD Anderson Cancer Center · USDartmouth College · USDuke Medical Center · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA093459NCI NIH HHS P50 CA093459 07
6 · The paper itself

Abstract

Recent investigation has identified association of IL-12p40 blood levels with melanoma recurrence and patient survival. No studies have investigated associations of single-nucleotide polymorphisms (SNPs) with melanoma patient IL-12p40 blood levels or their potential contributions to melanoma susceptibility or patient outcome. In the current study, 818,237 SNPs were available for 1,804 melanoma cases and 1,026 controls. IL-12p40 blood levels were assessed among 573 cases (discovery), 249 cases (case validation), and 299 controls (control validation). SNPs were evaluated for association with log[IL-12p40] levels in the discovery data set and replicated in two validation data sets, and significant SNPs were assessed for association with melanoma susceptibility and patient outcomes. The most significant SNP associated with log[IL-12p40] was in the IL-12B gene region (rs6897260, combined P=9.26 × 10(-38)); this single variant explained 13.1% of variability in log[IL-12p40]. The most significant SNP in EBF1 was rs6895454 (combined P=2.24 × 10(-9)). A marker in IL12B was associated with melanoma susceptibility (rs3213119, multivariate P=0.0499; OR=1.50, 95% CI 1.00-2.24), whereas a marker in EBF1 was associated with melanoma-specific survival in advanced-stage patients (rs10515789, multivariate P=0.02; HR=1.93, 95% CI 1.11-3.35). Both EBF1 and IL12B strongly regulate IL-12p40 blood levels, and IL-12p40 polymorphisms may contribute to melanoma susceptibility and influence patient outcome.

Indexed as

Genetic Predisposition to DiseaseAgedCase-Control StudiesConfidence IntervalsFemaleGenotypeHumansInterleukin-12 Subunit p40MaleMelanomaMiddle AgedMultivariate AnalysisPolymorphism, Single NucleotidePrognosisReproducibility of ResultsRisk AssessmentIL12B protein, humanInterleukin-12 Subunit p40

Identifiers

PMID25848976
PMCPMC4580731
OpenAlexW2151437270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.